Tesamorelin

Tesamorelin is a 6.0–6.5/10 fit for body composition, hormonal, metabolic health, especially for readers who can match the protocol to HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. The best evidence anchors are Badran et al. 2026, which Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass, and Russo et al. 2024, which INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold. Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.0–6.5/10.

✅ Best for: Adults with HIV-associated abdominal lipodystrophy who fit the FDA-labeled indication and can access prescription Egrifta SV with clinician monitoring. Tesamorelin is also worth discussing for HIV-associated NAFLD or early MASH under hepatology or infectious-disease supervision, especially when liver fat is imaging-confirmed. Select older adults or MCI patients with low-normal IGF-1 may reasonably track the cognitive research, but cognition should remain secondary. Best-case users monitor IGF-1, HbA1c, fasting glucose, edema, arthralgia, retinopathy risk, and cancer history while using tesamorelin as part of a broader body composition and metabolic health plan.

❌ Avoid if: Avoid tesamorelin with active malignancy, prior malignancy without oncology clearance, pregnancy, trying to conceive, hypothalamic-pituitary disruption, severe or active diabetic retinopathy, poorly controlled diabetes, acute critical illness, or prior hypersensitivity to tesamorelin or mannitol. Competitive athletes should avoid tesamorelin because WADA prohibits growth hormone-releasing factors at all times. Also avoid tesamorelin if the goal is casual weight loss, rapid aesthetics, unmonitored longevity experimentation, or cheap gray-market peptide use. If you cannot commit to daily injections, lab monitoring, and months-long tracking, a lower-friction sleep or metabolic intervention is a better first move. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.